Skip to content

Author

Li Ding

We have 2 of 3 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

KLHL1 suppresses triple-negative breast cancer progression by promoting M1 macrophage polarization via APOC2 degradation.

Findings reveal that activation of the KLHL1/APOC2 axis enhances M1 macrophage polarization and inhibits TNBC progression, providing novel insights into the immune regulatory mechanisms underlying TNBC development.

Zi-Ran He, Zhen-Hua Zhang, Li Ding et al. · 0 citations
Review Jul 2026

CDK4/6-Based Drug Research and Development: A Four-Year Update.

In-depth understanding of CDK4/6 inhibitors and the continuous development of bifunctional agents and protein degraders provides key theoretical and technical support for the design of next-generation therapeutic strategies to address current clinical limitations.

Miao-Xia Pu, Wenbo Xu, Li Ding et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.